Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  KOREA EXCHANGE (KOSDAQ)  >  Seegene Inc    A096530   KR7096530001

SEEGENE INC

(A096530)
  Report
 SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Financials (KRW)
Sales 2019 123 B
EBIT 2019 24,0 B
Net income 2019 25,2 B
Finance 2019 42,5 B
Yield 2019 -
Sales 2020 138 B
EBIT 2020 26,6 B
Net income 2020 21,4 B
Finance 2020 58,6 B
Yield 2020 -
P/E ratio 2019 36,0x
P/E ratio 2020 44,1x
EV / Sales2019 7 040x
EV / Sales2020 6 262x
Capitalization 864 B
More Financials
Company
Seegene, Inc. is a Korea-based company engaged in the development of molecular diagnostic reagents. The Company mainly provides infectious pathogens inspection products, including allergic respiratory pathogens, sexually transmitted diseases pathogens, human papilloma virus (HPV) and other... 
More about the company
Surperformance© ratings of Seegene Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on SEEGENE INC
02/18SEEGENE : launches KFDA Approved COVID-19 Assay
AQ
2016SEEGENE : Technologies to Unleash Customized Multiplex PCR Solutions and Support..
BU
2015SEEGENE : and BD Form Worldwide Collaboration to Develop Multiplex Molecular Dia..
MW
2015SEEGENE : and QIAGEN Enter Into a Collaboration to Develop Multiplex Molecular D..
MW
2015SEEGENE : Receives CE Mark for First Comprehensive Real-Time PCR Gastrointestina..
MW
2015SEEGENE : to Attend ECCMID 2015 Annual Meeting
MW
2015SEEGENE : Establishes U.S. Subsidiary
MW
2015SEEGENE : Receives Health Canada Approval for Its New Allplex(TM) Respiratory Mo..
MW
2015SEEGENE : Receives FDA Clearance for Its Herpes Simplex Virus Molecular Test
MW
2015SEEGENE : to Present at the 33rd Annual J.P. Morgan Healthcare Conference
MW
2014SEEGENE : Announces Publication of MuDT(TM) Technology in Nature's Scientific Re..
MW
2014SEEGENE : Receives US Patent for TOCE(TM) Technology
MW
2014SEEGENE : Introduces Allplex(TM) Assays Based on MuDT(TM) Next-Generation qPCR T..
MW
2014SEEGENE : to Unveil at AACC 2014 the Innovative Real-Time PCR Technology That Do..
BU
2014SEEGENE : Announces the World's First Real-time PCR Technology for Multi-Ct in a..
BU
More news
News in other languages on SEEGENE INC

- No features available -

More news
Sector news : Bio Diagnostics & Testing
03:22aNEW CHINESE BILLIONAIRES OUTPACE U.S : Hurun
RE
02/25GILEAD SCIENCES : First U.S. Testing Begins for Potential Coronavirus Treatment
DJ
02/25Regeneron Up Nearly 6%, Best Performer in the Nasdaq 100 So Far Today -- Data..
DJ
02/24J&J, Sanofi, Inovio Hunt for Coronavirus Vaccines
DJ
02/24LONZA : France's Sanofi to carve out active drug ingredients business
RE
More sector news : Bio Diagnostics & Testing
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 34 142,86  KRW
Last Close Price 33 250,00  KRW
Spread / Highest target 29,3%
Spread / Average Target 2,69%
Spread / Lowest Target -24,8%
EPS Revisions
Managers
NameTitle
Jong-Yoon Chun Chief Executive Officer & Director
Jong-Ki Chun Director
Kyung-Jun Chun Director
Hong-Il Yoon Independent Director
Hyun Baek Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SEEGENE INC711
EXACT SCIENCES CORPORATION3.33%12 804
GUARDANT HEALTH, INC.7.87%7 144
GENSCRIPT BIOTECH CORPORATION2.16%4 112
IOVANCE BIOTHERAPEUTICS, INC.13.66%3 970
INVITAE CORPORATION37.01%2 040